Concomitant targeting of the mTOR/MAPK pathways: novel therapeutic strategy in subsets of RICTOR/KRAS-altered non-small cell lung cancer
Dennis Ruder,Vassiliki Papadimitrakopoulou,Kazuhiko Shien,Carmen Behrens,Neda Kalhor,Huiqin Chen,Li Shen,J Jack Lee,Waun Ki Hong,Ximing Tang,Luc Girard,John D Minna,Lixia Diao,Jing Wang,Barbara Mino,Pamela Villalobos,Jaime Rodriguez-Canales,Nana E Hanson,James Sun,Vincent Miller,Joel Greenbowe,Garrett Frampton,Roy S Herbst,Veera Baladandayuthapani,Ignacio I Wistuba,Julie G Izzo
DOI: https://doi.org/10.18632/oncotarget.26129
2018-09-21
Oncotarget
Abstract:Despite a therapeutic paradigm shift into targeted-driven medicinal approaches, resistance to therapy remains a hallmark of lung cancer, driven by biological and molecular diversity. Using genomic and expression data from advanced non-small cell lung cancer (NSCLC) patients enrolled in the BATTLE-2 clinical trial, we identified RICTOR alterations in a subset of lung adenocarcinomas and found RICTOR expression to carry worse overall survival. RICTOR-altered cohort was significantly enriched in KRAS/MAPK axis mutations, suggesting a co-oncogenic driver role in these molecular settings. Using NSCLC cell lines, we showed that, distinctly in KRAS mutant backgrounds, RICTOR blockade impairs malignant properties and generates a compensatory enhanced activation of the MAPK pathway, exposing a unique therapeutic vulnerability. In vitro and in vivo concomitant pharmacologic inhibition of mTORC1/2 and MEK1/2 resulted in synergistic responses of anti-tumor effects. Our study provides evidence of a distinctive therapeutic opportunity in a subset of NSCLC carrying concomitant RICTOR/KRAS alterations.